We are developing a small molecule (DBI -500) to address epicardial adipose inflammation that is associated with primary atrial fibrillation (AF) and the recurrence of AF following cardiac ablation procedures.

DBI-500 significantly reduces the expression of cytokines associated with inflammation and thus reduces cardiovascular and metabolic risk.

DBI is an ideal oral small molecule for use independently or in combination with current therapy to address the root cause of diseases such as Atrial Fibrillation and may also be indicated in the treatment of Type 2 Diabetes, Obesity, and NASH.